Huang Zhen-Gui, Bai Song, Chen Li, Wang Jiang-Tao, Ding Bo-Ping
Department of Pharmacology & Pharmacology of Traditional Chinese Medicine Grade Three Laboratory, State Administration of Traditional Chinese Medicine of China, Wannan Medical College, Wuhu 241002, China.
Zhongguo Zhong Yao Za Zhi. 2013 Feb;38(3):381-5.
To explore the effect of puerarin combined with felodipine on the mRNA and protein expression of apelin and APJ in renal tissue of renovascular hypertensive rat.
Sixty-two Sprague-Dawley rats were used, of which 8 rats were randomly chosen as sham-operation group. The remaining rats were made for the rat model with renovascular hypertension. The renovascular hypertensive rats were randomly divided into 5 groups as follows: 4 groups which were treated with felodipine (0.8 mg x kg(-1) x d(-1)), puerarin (50 mg x kg(-1) x d(-1)), puerarin combined with felodipine (puerarin 25 mg x kg(-1) x d(-1) + felodipine 0.4 mg x kg(-1) x d(-1)) or captopril combined with felodipine (captopril 15 mg x kg(-1) x d(-1) x felodipine 0.4 mg x kg(-1) x d(-1)), and 1 group which was treated with distilled water. Drugs or distilled water were administered for 8 weeks. The expression of apelin and APJ mRNA and protein in ischemic and non-ischemic kidneys was assessed by RT-PCR or Western blot.
Compared with sham-operation group, the expression of apelin mRNA and protein in ischemic and non-ischemic kidneys in model group was increased significantly (P < 0.01); the expression of APJ mRNA and protein in ischemic kidneys had no significance, while that in non-ischemic kidneys was decreased (P < 0. 01). Compared with model group, the expression of apelin mRNA and protein in ischemic and non-ischemic kidneys was decreased significantly in all drug-treated groups (P < 0.01); while that of APJ mRNA and protein in non-ischemic kidneys was upregulated (P < 0.01). Compared with felodipine group, the expression of apelin mRNA and protein in ischemic and non-ischemic kidneys was decreased (P < 0.01 or P < 0.05) in the group treated with both puerarin and felodipine; and the expression of APJ mRNA and protein in ischemic kidneys did not reach significant level, however, that was upregulated in non-ischemic kidneys (P < 0.01 or P < 0.05).
Puerarin downregulates the expression of apelin mRNA and protein in ischemic and non-ischemic kidneys, and upregulates that of APJ mRNA and protein in non-ischemic kidneys. Combination of puerarin and felodipine enhances the above-mentioned effects and shows no significant difference versus the combination of felodipine and captopril. The results suggest that puerarin regulates blood pressure and protects target organ through apelin/APJ pathway and that puerarin has synergetic effects with CCB.
探讨葛根素联合非洛地平对肾血管性高血压大鼠肾组织中apelin及APJ的mRNA和蛋白表达的影响。
选用62只Sprague-Dawley大鼠，其中8只随机选取作为假手术组。其余大鼠制备肾血管性高血压大鼠模型。将肾血管性高血压大鼠随机分为5组：4组分别给予非洛地平（0.8mg·kg-1·d-1）、葛根素（50mg·kg-1·d-1）、葛根素联合非洛地平（葛根素25mg·kg-1·d-1 + 非洛地平0.4mg·kg-1·d-1）或卡托普利联合非洛地平（卡托普利15mg·kg-1·d-1 + 非洛地平0.4mg·kg-1·d-1），1组给予蒸馏水。药物或蒸馏水给药8周。采用RT-PCR或Western blot法检测缺血及非缺血肾组织中apelin和APJ mRNA及蛋白的表达。
与假手术组相比，模型组缺血及非缺血肾组织中apelin mRNA和蛋白表达显著增加（P < 0.01）；缺血肾组织中APJ mRNA和蛋白表达无显著差异，而非缺血肾组织中APJ mRNA和蛋白表达降低（P < 0.01）。与模型组相比，各药物治疗组缺血及非缺血肾组织中apelin mRNA和蛋白表达均显著降低（P < 0.01）；而非缺血肾组织中APJ mRNA和蛋白表达上调（P < 0.01）。与非洛地平组相比，葛根素联合非洛地平组缺血及非缺血肾组织中apelin mRNA和蛋白表达降低（P < 0.01或P < 0.05）；缺血肾组织中APJ mRNA和蛋白表达未达显著水平，但非缺血肾组织中APJ mRNA和蛋白表达上调（P < 0.01或P < 0.05）。
葛根素下调缺血及非缺血肾组织中apelin mRNA和蛋白表达，上调非缺血肾组织中APJ mRNA和蛋白表达。葛根素与非洛地平联合使用可增强上述作用，与非洛地平联合卡托普利相比无显著差异。结果提示葛根素通过apelin/APJ途径调节血压并保护靶器官，且葛根素与CCB具有协同作用。
